Making use of the primary tumour

Arnold Baars, Jan Buter, Herbert M. Pinedo

Research output: Contribution to journalArticlepeer-review


Surgical resection of a primary tumour is often not sufficient to cure a patient. Even when no residual cancer can be detected at time of surgery, metastases may appear in the following years, which indicates that the primary tumour had apparently spread before surgery. Following surgery, systemic chemotherapy may be used to eradicate micro-metastatic disease. Here we present two unconventional strategies that implement new insights into tumour biology and tumour immunology in the treatment of patients with cancer. Both experimental strategies use the individual characteristics of the patient's primary tumour to optimise the control of life-threatening micro-metastases. We aim to modulate the patient's adaptive immune system, targeting it towards the patient's own tumour cells to eradicate residual disease following local treatment. In one approach, this is done by autologous tumour cell vaccinations as adjuvant treatment for colon cancer patients and, in a second approach, by giving chemo-imunotherapy before local treatment to women with locally advanced breast cancer.

Original languageEnglish (US)
Pages (from-to)79-86
Number of pages8
Issue number1
StatePublished - Jan 1 2003
Externally publishedYes

ASJC Scopus subject areas

  • Plant Science
  • Agricultural and Biological Sciences (miscellaneous)
  • Developmental Biology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Cell Biology
  • Biochemistry
  • Neuroscience (miscellaneous)


Dive into the research topics of 'Making use of the primary tumour'. Together they form a unique fingerprint.

Cite this